Drilldown: Medicines
Appearance
Medicines > onset
:
1–2 h
or
Over weeks
or
Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks 
:
1–2 h
or
Over weeks
or
Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks 
Use the filters below to narrow your results.
Anti-CGRP ligand monoclonal antibody (2) ·
Beta Blocker (2) ·
Cardioselective (β1) (1) ·
Cardioselective (β1) + vasodilator (1) ·
[[:Category:Antifolates|Antifolate]] (1) ·
[[:Category:Antineoplastics|Antineoplastic]] (1) ·
[[:Category:DMARDs|DMARD]] (1) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (1)
None (1) ·
Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1)
Preventive treatment of migraine in adults (episodic and chronic) (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) ·
'"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"' (1)
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
5 mg daily (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific (1)
'''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (2) ·
Limited data; avoid (2)
Showing below up to 5 results in range #1 to #5.

